Imamura Teruhiko, Fukumoto Yoshihiro, Adachi Hitoshi, Momomura Shin-Ichi, Yasumura Yoshio, Hidaka Takayuki, Kasai Takatoshi, Kinugawa Koichiro, Kihara Yasuki
Second Department of Internal Medicine, Toyama University, 2630 Sugitani, Toyama, 930-0194, Japan.
Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School, Kurume, Japan.
Heart Vessels. 2025 Mar;40(3):235-244. doi: 10.1007/s00380-024-02457-8. Epub 2024 Sep 22.
The clinical ramifications of adaptive servo-ventilation (ASV) therapy have stirred debate within the medical community. Given the potential detrimental effect of elevated expiratory positive airway pressure (EPAP) on cardiac output, we hypothesized that relatively lower EPAP may be recommended for successful ASV therapy. In-hospital patients with congestive heart failure refractory to medical therapy were included in the prospective cohort study of ASV therapy on prognosis in repeatedly hospitalized patients with chronic heart failure: longitudinal observational study of effects on readmission and mortality (SAVIOR-L) study. Assignment to either the ASV treatment group or the medical management group was at the discretion of the attending physicians. For the purposes of this retrospective study, our focus remained solely on the ASV cohort. We conducted an extensive analysis to elucidate the influence of lower EPAP settings on midterm mortality. A total of 108 patients were included. The median age was 74 years, and 83 (77%) patients were male. The median EPAP setting employed was 4 cmHO, with 60 patients subjected to EPAP levels below 5 cmHO. There were no significant differences in the baseline characteristics between the lower and higher EPAP groups, which were divided at the EPAP cutoff of 4.5 cmHO (p > 0.05 for all). A trend toward reduced mortality emerged among patients with EPAP settings below 5 cmHO, exhibiting a hazard ratio of 0.48 (95% confidence interval 0.22-1.07, p = 0.072) after adjusting for potential confounding factors: 2-year mortality 26% vs. 38%; p = 0.095. Heart failure readmission rates were not significantly different between the two groups (p = 0.61). The adoption of relatively lower EPAP settings during ASV therapy may be advisable. Such an approach has the potential to ameliorate mortality rates while concurrently maintaining heart failure recurrence rates at levels commensurate with those with default EPAP settings.
适应性伺服通气(ASV)治疗的临床影响在医学界引发了争论。鉴于呼气末正压(EPAP)升高对心输出量可能产生的有害影响,我们推测,对于成功的ASV治疗,可能推荐相对较低的EPAP。因心力衰竭住院且药物治疗无效的患者被纳入一项关于ASV治疗对反复住院的慢性心力衰竭患者预后影响的前瞻性队列研究:对再入院和死亡率影响的纵向观察研究(SAVIOR-L)。分配到ASV治疗组或药物治疗组由主治医师自行决定。在这项回顾性研究中,我们仅关注ASV队列。我们进行了广泛分析,以阐明较低EPAP设置对中期死亡率的影响。共纳入108例患者。中位年龄为74岁,83例(77%)为男性。所采用的EPAP设置中位数为4 cmH₂O,60例患者的EPAP水平低于5 cmH₂O。较低和较高EPAP组的基线特征无显著差异,两组按EPAP临界值4.5 cmH₂O划分(所有p>0.05)。EPAP设置低于5 cmH₂O的患者死亡率有降低趋势,在调整潜在混杂因素后,风险比为0.48(95%置信区间0.22 - 1.07,p = 0.072):2年死亡率分别为26%和38%;p = 0.095。两组之间心力衰竭再入院率无显著差异(p = 0.61)。在ASV治疗期间采用相对较低的EPAP设置可能是可取的。这种方法有可能降低死亡率,同时将心力衰竭复发率维持在与默认EPAP设置相当的水平。